Prostate Cancer

Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.

Cleveland Clinic highlights its use of irreversible electroporation, also known as Nanoknife, in select patients with prostate cancer.

Yale School of Medicine Associate Professor of Urology Michael Leapman, MD, MHS, and coauthors estimated the environmental impacts of prostate MRI and prostate biopsy.

"We found a sizeable and statistically significant uptick in compliance with genetic testing and compliance with post-test genetic counseling in patients who underwent testing after the implementation of the standardized protocol," says Siddharth Ramanathan.

"It will only be when the indications for focal therapy are expanded to higher-grade and larger tumors that we will begin to learn about the true efficacy of this approach," writes Badar M. Mian, MD.

Treatment with rucaparib reduced risk of imaging-based progression or death by half in men with BRCA-altered metastatic castration-resistant prostate cancer.

The combination use of niraparib plus abiraterone and prednisone continued to improve outcomes in patients with metastatic, castration-resistant prostate cancer and HRR gene alterations.

Expert perspectives on strategies to optimize communication, both between healthcare professionals and with patients who present with prostate cancer.

Cardiologist Anees A. Daud, MD, breaks down the typical patient with prostate cancer seen at his practice.

Urologist David Morris, MD, FACS, defines the typical patient with prostate cancer treated at his practice.

Oncologist Joelle Hamilton, MD, shares her perspective on the typical patient with prostate cancer seen at her institution.

Centering focus on a patient case of cardiovascular risk and prostate cancer, experts share their perspective on management strategies.

Comprehensive insight regarding strategies to mitigate cardiovascular risk in patients on therapy for prostate cancer.

Shared insight on a timeline of clinical studies contextualizing cardiovascular disease in the setting of prostate cancer management.

Expert perspectives on the risk of cardiovascular disease as it exists in the context of androgen deprivation therapy (ADT) and prostate cancer.

"We found that if the patient has normal IsoPSA, he has only 1% of risk of developing clinically significant prostate cancer in a median follow-up time of 18 months," says Nour Abdallah, MD.

The GPS test uses a 17-gene signature to predict disease aggressiveness and help guide treatment decisions for patients with localized prostate cancer.

"The reason that we really focus on prostate cancer is because it's amenable to early screening. Early detection is key in cure," says Janet Kukreja, MD, MPH, FACS.

IsoPSA is included in the National Comprehensive Cancer Network Prostate Cancer guidelines for early detection of the disease.

Barrigel is a hyaluronic acid rectal spacer indicated for patients with T1 to T3b prostate cancer disease.

Closing out his review of imaging modalities in the setting of prostate cancer, Brian Helfand, MD, PhD, looks toward future evolutions in detection and treatment.

Expert perspective on next steps for physicians and patients following a negative imaging result when recurrent prostate cancer is suspected.

Moving on to the second patient case of prostate cancer, Brian Helfand, MD, PhD, shares context for negative imaging results in this setting.

A brief discussion on how selection of imaging should be approached for patients receiving androgen deprivation therapy (ADT) for prostate cancer.

Following his review of available imaging modalities, Brian Helfand, MD, PhD, considers which scans are most appropriate based on patient and disease factors.